李氏大藥廠(00950.HK)聯營眼科產品招募首名臨床試驗對象
李氏大藥廠(00950.HK)公布,聯營公司兆科眼科於中國成功招募首名病人在II期臨床試驗中使用滴眼液ZKY001。該產品通過抗炎作用及刺激上皮細胞遷移,治療角膜上皮缺損,為中國目前唯一的臨床階段角膜上皮缺損候選藥物。
此臨床試驗的設計為招募合共105名對象,於完成該項I期臨床試驗後,兆科眼科已就啟動II期臨床試驗諮詢國家藥監局藥審中心,溝通後藥審中心認為目前可得數據充分表明ZKY001的安全特性,可開展後續的試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.